Alan Collis joined as the leader of the SynVent team. SynVent is Syngene’s platform for integrated discovery and early development, delivering upon strategies built in collaboration with and on behalf of clients to advance novel molecules into clinical trials. He is responsible for the formulation and implementation of Syngene’s overall Integrated Drug Discovery (IDD) scientific strategy and oversees the end-to-end execution of client programs.
Sign up to view 0 direct reports
Get started